However, since ER-negative HER2-positive DCIS lesions likely identify high-grade or recurrent disease [33], this study gives valuable insight into the proportion of DCIS tumors most urgently requiring drug targeting in patients. This evidence concerns the gene ESR1 and ductal breast carcinoma in situ.